Selective prescribing of atypical antipsychotics

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 1, 2005, Pages 25-30

  Breekveldt Postma, Nancy S ^a   Schillevoort, Igor ^b   Nolen, Willem A ^c   Veraart, Christian P W M ^d   Herings, Ron M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Eli Lilly Nederland   (Netherlands)

Author keywords

Antipsychotics; Atypical; Channelling; Extrapyramidal side effects; Prescription database

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERPHENAZINE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NETHERLANDS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CHOLINERGIC ANTAGONISTS; CLOZAPINE; DELAYED-ACTION PREPARATIONS; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; MEDICAL RECORDS, PROBLEM-ORIENTED; MIDDLE AGED; NETHERLANDS; PATIENT SELECTION; PHARMACOEPIDEMIOLOGY; RISPERIDONE; TREATMENT OUTCOME;

EID: 11844273287     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1037     Document Type: Article

References (18)

1. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10(4): 577-581.
2. Egberts AC, Lenderink AW, de Koning FH, Leufkens HG. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J Clin Psychopharmacol 1997; 17(3): 149-155.
3. Beasley CM, Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7 2): 125-137.
4. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156(1): 79-87.
5. Tollefson GD, Beasley CM, Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154 4): 457-465.
6. McGrath J, Emmerson WB. Fortnightly review: treatment of schizophrenia. Br Med J 1999; 319(7216): 1045-1048.
7. Herings R. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Thesis Utrecht University: Utrecht, 1993; 232.
8. Keks NA, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust NZ J Psychiatry 1999; 33(6): 896-901.
9. EGRET, [computer program]. Seattle: Cytel Software Corporation, 1999.
10. Emsley R. Role of newer atypical antipsychotics in the management of treatment-resistant schizophrenia. CNS Drugs 2000; 13(6): 409-420.
11. CVZ. Farmacotherapeutisch Kompas: medisch farmaceutische voorlichting/uitgave van de Commissie Farmaceutische Hulp van het College voor zorgverzekeringen 1999. Amstelveen, 1999.
12. Ohaeri JU. Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder. East Afr Med J 2000; 77(2): 86-92.
13. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58(5): 205-211.
14. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995; 10(4): 239-244.
15. Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000; 12 1): 11-18.
16. Allan ER, Sison CE, Alpert M, Connolly B, Crichton J. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull 1998; 34(1): 71-74.
17. Movig KL, Egberts AC, Lenderink AW, Leufkens HG. Selective prescribing of spasmolytics. Ann Pharmacother 2000; 34(6): 716-720.
18. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57(Suppl. 11): 68-71.